JP2015504057A5 - - Google Patents

Download PDF

Info

Publication number
JP2015504057A5
JP2015504057A5 JP2014550478A JP2014550478A JP2015504057A5 JP 2015504057 A5 JP2015504057 A5 JP 2015504057A5 JP 2014550478 A JP2014550478 A JP 2014550478A JP 2014550478 A JP2014550478 A JP 2014550478A JP 2015504057 A5 JP2015504057 A5 JP 2015504057A5
Authority
JP
Japan
Prior art keywords
chromen
pyrazin
pyridin
methylimidazo
dimethylimidazo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014550478A
Other languages
English (en)
Japanese (ja)
Other versions
JP6193881B2 (ja
JP2015504057A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/071899 external-priority patent/WO2013101974A1/en
Publication of JP2015504057A publication Critical patent/JP2015504057A/ja
Publication of JP2015504057A5 publication Critical patent/JP2015504057A5/ja
Application granted granted Critical
Publication of JP6193881B2 publication Critical patent/JP6193881B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014550478A 2011-12-30 2012-12-28 脊髄性筋萎縮症を治療するための化合物 Active JP6193881B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161582064P 2011-12-30 2011-12-30
US61/582,064 2011-12-30
PCT/US2012/071899 WO2013101974A1 (en) 2011-12-30 2012-12-28 Compounds for treating spinal muscular atrophy

Publications (3)

Publication Number Publication Date
JP2015504057A JP2015504057A (ja) 2015-02-05
JP2015504057A5 true JP2015504057A5 (enExample) 2016-02-12
JP6193881B2 JP6193881B2 (ja) 2017-09-06

Family

ID=48698624

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014550478A Active JP6193881B2 (ja) 2011-12-30 2012-12-28 脊髄性筋萎縮症を治療するための化合物

Country Status (10)

Country Link
US (2) USRE47689E1 (enExample)
EP (1) EP2797592B1 (enExample)
JP (1) JP6193881B2 (enExample)
KR (1) KR102057351B1 (enExample)
CN (1) CN104244944B (enExample)
BR (1) BR112014016287B1 (enExample)
CA (1) CA2861609C (enExample)
EA (1) EA029984B1 (enExample)
MX (1) MX352861B (enExample)
WO (1) WO2013101974A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2733644T3 (es) 2012-01-26 2019-12-02 Ptc Therapeutics Inc Compuestos para tratar atrofia muscular espinal
JP6092897B2 (ja) 2012-02-10 2017-03-08 ピーティーシー セラピューティクス, インコーポレイテッド 脊髄性筋萎縮症を治療するための化合物
EA029155B1 (ru) 2012-03-01 2018-02-28 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения спинальной мышечной атрофии
CA2868026C (en) 2012-03-23 2021-02-16 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
MX2015008146A (es) * 2012-12-24 2016-01-20 Univ Ramot Agentes para tratar enfermedades geneticas derivadas de mutaciones sin sentido y metodos para identificarlas.
CN103360269B (zh) * 2013-07-16 2015-07-08 临海市联盛化学有限公司 一种3-氯-2-氨基苯酚的制备方法
CN105392790B (zh) 2013-08-19 2019-04-19 豪夫迈·罗氏有限公司 4H-吡啶并[1,2-a]嘧啶-4-酮化合物制备用于预防或治疗癌症的药物的用途
EP3082820B1 (en) 2013-12-19 2022-07-20 PTC Therapeutics, Inc. Methods for modulating the amount of rna transcripts
WO2015095449A1 (en) * 2013-12-19 2015-06-25 Ptc Therapeutics, Inc. Methods for modulating the amount rna transcripts
EP3134388B1 (en) 2014-04-22 2019-01-09 Universität Basel Novel manufacturing process for triazine, pyrimidine and pyridine derivatives
US10882868B2 (en) 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
DK3143025T3 (da) * 2014-05-15 2019-12-09 Hoffmann La Roche Forbindelser til behandling af spinal muskelatrofi
CA2952895C (en) * 2014-06-25 2023-09-26 F. Hoffmann-La Roche Ag Imidazo[1,2-a]pyrazin-1yl-benzamide compounds for treating spinal muscular atrophy
CN104803921A (zh) * 2015-03-14 2015-07-29 长沙深橙生物科技有限公司 一种苯取代嘧啶衍生物的制备方法
CN104744376A (zh) * 2015-03-14 2015-07-01 长沙深橙生物科技有限公司 一种2-异丙基嘧啶衍生物的制备方法
EP4249472A3 (en) 2015-05-30 2023-12-13 PTC Therapeutics, Inc. Methods for modulating rna splicing
JP2018533594A (ja) * 2015-11-12 2018-11-15 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 筋萎縮性側索硬化症を処置するための化合物
JP6659841B2 (ja) 2015-11-12 2020-03-04 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 脊髄性筋萎縮症を処置するための組成物
WO2017087364A1 (en) * 2015-11-16 2017-05-26 Ptc Therapeutics, Inc. Hydrogen isotope-enriched analogues of 1,2,4-oxandiazole benzoic acid compounds, compositions and uses thereof
CN110946865B (zh) 2015-12-10 2024-01-26 Ptc医疗公司 用于治疗亨廷顿病的方法
EP3386978B1 (en) 2015-12-10 2021-01-27 H. Hoffnabb-La Roche Ag Bridged piperidine derivatives
BR112018017077A2 (pt) * 2016-02-23 2018-12-26 Univ Indiana Res & Tech Corp terapias de combinação para tratamento de atrofia muscular espinhal
US10906905B2 (en) 2016-10-14 2021-02-02 Jiangsu Hengrui Medicine Co., Ltd. Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof
WO2018098446A1 (en) 2016-11-28 2018-05-31 Ptc Therapeutics, Inc Methods for modulating rna splicing
EP3634953B1 (en) 2017-06-05 2024-01-03 PTC Therapeutics, Inc. Compounds for treating huntington's disease
BR112019026508A2 (pt) 2017-06-14 2020-07-14 Ptc Therapeutics, Inc. métodos para modificar o splicing do rna
MX2019015578A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
CN111163838B (zh) 2017-06-28 2023-03-28 Ptc医疗公司 用于治疗亨廷顿氏病的方法
RU2020105929A (ru) 2017-08-04 2021-09-06 Скайхоук Терапьютикс, Инк. Способы и композиции для модулирования сплайсинга
SG11202002610TA (en) 2017-09-22 2020-04-29 Hoffmann La Roche Process for the prepration of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives
KR20200143376A (ko) 2018-03-13 2020-12-23 샤이어 휴먼 지네틱 테라피즈 인크. 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도
JP7399870B2 (ja) 2018-03-27 2023-12-18 ピーティーシー セラピューティクス, インコーポレイテッド ハンチントン病を処置するための化合物
EP3814360B8 (en) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
PL3814357T3 (pl) 2018-06-27 2024-09-16 Ptc Therapeutics, Inc. Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona
CA3105174A1 (en) 2018-06-27 2020-01-02 Reborna Biosciences, Inc. Prophylactic or therapeutic agent for spinal muscular atrophy
KR20210038845A (ko) 2018-06-27 2021-04-08 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료를 위한 헤테로아릴 화합물
US20220071953A1 (en) * 2019-01-08 2022-03-10 Texas Tech University System Small Molecule Analogs Of The Protein E4ORF1 In The Treatment And Prevention Of Metabolic Disorders
JP7603592B2 (ja) 2019-02-05 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
EP3920926A4 (en) 2019-02-05 2022-10-19 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN119638696A (zh) 2019-02-06 2025-03-18 斯基霍克疗法公司 用于调节剪接的方法和组合物
WO2020163544A1 (en) 2019-02-06 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
MX2020013384A (es) 2019-03-01 2021-04-28 Illumina Cambridge Ltd Compuestos de comarina sustituidos con amina exocíclica y sus usos como etiquetas fluorescentes.
CN109943092A (zh) * 2019-04-09 2019-06-28 浙江工业大学 具有高荧光量子产率的咪唑类香豆素类染料及其合成方法
CN114245794B (zh) 2019-05-13 2024-09-13 Ptc医疗公司 用于治疗亨廷顿氏病的化合物
US11129829B2 (en) 2019-06-17 2021-09-28 Skyhawk Therapeutics, Inc. Methods for modulating splicing
WO2021055589A1 (en) 2019-09-18 2021-03-25 Shire Human Genetic Therapies, Inc. Heteroaryl plasma kallikrein inhibitors
ES2987744T3 (es) 2019-09-18 2024-11-18 Takeda Pharmaceuticals Co Inhibidores de calicreína plasmática y usos de los mismos
CN110862395B (zh) * 2019-11-13 2020-09-29 株洲千金药业股份有限公司 一种制备他达拉非重要杂质的原料化合物的制备方法
CN114315807B (zh) * 2022-01-05 2023-09-15 江南大学 一种吡啶鎓盐光引发剂及其制备方法和应用
CN121488042A (zh) * 2023-06-09 2026-02-06 豪夫迈·罗氏有限公司 诱导型基因表达系统
US12180195B1 (en) 2023-11-01 2024-12-31 King Faisal University 6-(6-bromo-2-oxo-2H-chromen-3-yl)-4-(2,4-dichlorophenyl)-2-alkoxynicotinonitrile as an antimicrobial compound
WO2025111409A1 (en) * 2023-11-21 2025-05-30 Biogen Ma Inc. Heterocyclic compounds of formula (i) for use in the treatment of spinal muscular atrophy via modulation of smn2 splicing

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1020636B (de) * 1954-11-12 1957-12-12 Geigy Ag J R Verfahren zur Herstellung von 3-Phenyl-7-acylamino-cumarinen
CH419146A (de) * 1961-04-27 1966-08-31 Geigy Ag J R Verfahren zur Herstellung von 3-Phenyl-7-pyrazolyl-cumarinen
US3311636A (en) * 1963-03-14 1967-03-28 Upjohn Co Organic chemical compounds and process
DE1245306B (de) 1963-05-11 1967-07-27 Bayer Ag Aufhellungsmittel
DE1594845C3 (de) 1966-03-19 1982-05-19 Bayer Ag, 5090 Leverkusen Substituierte v-Triazol-(2)-yl-cumarinverbindungen und deren Verwendung als Aufhellungsmittel
CH505089A (de) * 1968-08-23 1971-03-31 Bayer Ag Verfahren zur Herstellung von 3-substituierten-7-Aminocumarinen
JPS5023687B2 (enExample) * 1972-03-07 1975-08-09
CH620322B (de) * 1976-03-26 Ciba Geigy Ag Verwendung von 3-phenyl-7-(v-triazol-2-yl)-cumarinen zum optischen aufhellen von organischen materialien.
FR2361680A1 (fr) * 1976-08-11 1978-03-10 Du Pont Plaques d'impression planographiques et leur preparation
DE2807761A1 (de) 1978-02-23 1979-08-30 Basf Ag Cumarinderivate
DE2815956A1 (de) * 1978-04-13 1979-10-18 Bayer Ag Verfahren zur herstellung von in 2-stellung substituierten triazolen-1,2,3
DE2950291A1 (de) * 1979-12-14 1981-06-19 Basf Ag, 6700 Ludwigshafen Neue cumarinverbindungen und verfahren zur herstellung von cumarinverbindungen
JPS56140990A (en) * 1980-04-07 1981-11-04 Showa Kagaku Kogyo Kk 3-phenylcoumarin derivative bearing dicarbonylimide group
DE3101141A1 (de) 1981-01-16 1982-09-02 Bayer Ag, 5090 Leverkusen Triazolylcumarinverbindungen, sowie deren herstellung und verwendung als optiche aufheller, scintillatoren und laserfarbstoffe
JPS62267285A (ja) 1986-05-16 1987-11-19 Kyorin Pharmaceut Co Ltd 新規ピラゾロピリジン誘導体
EP0428939B1 (de) * 1989-11-21 1996-01-17 Bayer Ag Cumarinderivate, Verfahren zu ihrer Herstellung, ihre Verwendung und Thiazolyl-essigsäurederivate als Zwischenprodukte
EP0429907B1 (de) 1989-11-21 1994-06-01 Bayer Ag Optischer Biosensor
EP0448241A3 (en) * 1990-02-28 1992-03-04 Konica Corporation Light-sensitive silver halide photographic material
CA2123740C (en) * 1993-05-19 2002-12-17 Hee-Gwon Chae Electric vacuum cleaner
JPH073179A (ja) * 1993-06-15 1995-01-06 Nippon Kayaku Co Ltd インクジェットプリント用インク組成物及びこれを用いる染色法
KR20040068240A (ko) * 2001-12-14 2004-07-30 노보 노르디스크 에이/에스 호르몬 민감성 리파아제의 활성을 감소시키기 위한 화합물및 그들의 사용
GB0205281D0 (en) * 2002-03-06 2002-04-17 Novartis Ag Organic compounds
CN1180016C (zh) * 2002-04-04 2004-12-15 中国石化上海石油化工股份有限公司 用于制造增白聚丙烯纤维的增白聚丙烯母粒
EP1550657A4 (en) * 2002-09-11 2009-12-30 Kureha Corp AMINO COMPOUNDS AND THEIR USE
WO2006078834A1 (en) 2005-01-21 2006-07-27 Janssen Pharmaceutica N.V. Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
US8337941B2 (en) * 2006-07-27 2012-12-25 The Trustees Of Columbia University In The City Of New York Fluorescent substrates for monoamine transporters as optical false neurotransmitters
WO2008074798A1 (en) * 2006-12-20 2008-06-26 Neurosearch A/S Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
JP2011511031A (ja) * 2008-02-05 2011-04-07 ノイロサーチ アクティーゼルスカブ 新規な9−アザ−ビシクロ[3.3.1]ノン−3−イルオキシクロメン−2−オン誘導体及びモノアミン神経伝達物質再取り込み阻害薬としてのそれらの使用
DE102008018132A1 (de) * 2008-04-09 2009-10-15 Henkel Ag & Co. Kgaa Kationische Direktzieher und Mittel zum Färben von keratinhaltigen Fasern
US8633019B2 (en) 2008-05-27 2014-01-21 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
WO2010019243A1 (en) 2008-08-13 2010-02-18 Ptc Therapeutics, Inc. Methods for treating viral infections
WO2010049044A1 (de) * 2008-10-29 2010-05-06 Merck Patent Gmbh Flüssigkristallanzeige
ES2733644T3 (es) 2012-01-26 2019-12-02 Ptc Therapeutics Inc Compuestos para tratar atrofia muscular espinal
JP6092897B2 (ja) 2012-02-10 2017-03-08 ピーティーシー セラピューティクス, インコーポレイテッド 脊髄性筋萎縮症を治療するための化合物
EA029155B1 (ru) 2012-03-01 2018-02-28 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения спинальной мышечной атрофии
CA2868026C (en) 2012-03-23 2021-02-16 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy

Similar Documents

Publication Publication Date Title
JP2015504057A5 (enExample)
JP2020522570A5 (enExample)
CN111182898B (zh) 用于治疗亨廷顿氏病的方法
JP2015508075A5 (enExample)
JP7649257B2 (ja) ハンチントン病を処置するための化合物
EP3645121B1 (en) Methods for treating huntington's disease
JP2022153413A (ja) Rnaスプライシングを調節する方法
JP2011500774A5 (enExample)
JP2014506929A5 (enExample)
IL271046B2 (en) Compounds for the treatment of Huntington's disease
JPWO2019191229A5 (enExample)
AU2013216870A1 (en) Compounds for treating spinal muscular atrophy
RU2018112230A (ru) Бициклические соединения в качестве ингибиторов atx
JPWO2020005877A5 (enExample)
HRP20120105T1 (hr) Aminoheterociklički spojevi
KR20140128310A (ko) 척수성 근위축증을 치료하기 위한 화합물
JP2016504363A5 (enExample)
RU2015131148A (ru) СОЕДИНЕНИЯ, ГЕТЕРОБИЦИКЛО-ЗАМЕЩЕННЫЕ-[1, 2, 4]ТРИАЗОЛО[1, 5c]ХИНАЗОЛИН-5-АМИНА, ОБЛАДАЮЩИЕ СВОЙСТВАМИ А2А АНТАГОНИСТОВ
RU2014123316A (ru) Ингибиторы фосфодиэстеразы типа 10а
JPWO2019191092A5 (enExample)
JP2020511412A5 (enExample)
JPWO2020065613A5 (enExample)
JPWO2022099144A5 (enExample)
NZ771342A (en) Heteroaryl compounds for treating huntington’s disease
NZ771342B2 (en) Heteroaryl compounds for treating huntington's disease